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Abstract
Alexander disease is a fatal neurological illness characterized by white-matter degeneration and formation of
Rosenthal fibers, which contain glial fibrillary acidic protein as astrocytic inclusion. Alexander disease is mainly
caused by a gene mutation encoding glial fibrillary acidic protein, although the underlying pathomechanism
remains unclear. We established induced pluripotent stem cells from Alexander disease patients, and differentiated
induced pluripotent stem cells into astrocytes. Alexander disease patient astrocytes exhibited Rosenthal fiber-like
structures, a key Alexander disease pathology, and increased inflammatory cytokine release compared to healthy
control. These results suggested that Alexander disease astrocytes contribute to leukodystrophy and a variety of
symptoms as an inflammatory source in the Alexander disease patient brain. Astrocytes, differentiated from induced
pluripotent stem cells of Alexander disease, could be a cellular model for future translational medicine.
Keywords: Alexander disease (AxD), Glial fibrillary acidic protein (GFAP), Induced pluripotent stem cells (iPSCs),
Disease modeling, Astrocytes, Rosenthal fibers, Heat-shock protein, Alpha-crystallin, Cytokine, Inflammatory response,
Inherited astrocytopathy
Introduction
Alexander disease (AxD) was first described by W. S.
Alexander [1]. The clinical phenotypes of AxD are
macrocephaly, frontal leukodystrophy and a variety of
developmental delays with epileptic seizures, dysphagia,
or bulbar/pseudobulbar signs. However, the severity of
these clinical features differs among patients, being
mostly dependent on the age of onset [2].
The common neuropathological feature of AxD is the
presence of Rosenthal fibers, a unique cytoplasmic inclu-
sion within astrocytes. Rosenthal fibers contain glial
fibrillary acidic protein (GFAP), major astrocytic inter-
mediate filament protein and molecular chaperones,
including alpha-B-crystallin and other heat shock pro-
teins [3, 4]. After extensive neuropathological investiga-
tions, missense mutations in GFAP have been identified as
a genetic basis for AxD [5]. The discovery of the GFAP
mutations opened the way to the development of model
systems using tissue culture cells and transgenic mice for
the study of AxD. Transgenic models recapitulated GFAP
aggregations. However, it remained unclear how AxD
mutations lead to protein aggregation in patient astrocytes
as well as how mutant GFAP-expressing astrocytes
contribute to neuronal degeneration [6].
In 2007, the discovery of a combination of transcription
factors that could reprogram somatic cells into cells exhi-
biting pluripotency, called induced pluripotent stem cells
(iPSCs), has provided researchers with a revolutionary tool
to study human biology and diseases [7]. iPSCs can be de-
rived from many somatic cell types, including easily access-
ible dermal fibroblasts and peripheral blood mononuclear
cells [8, 9]. Similar to human embryonic stem cells
(hESCs), iPSCs can self-renew and expand indefinitely in
culture [7]. More importantly, they share the capacity to
generate any cell types in the body, a property that is par-
ticularly useful for the study of neurological diseases. The
pluripotency of iPSCs enables the production of astrocytes
for disease modeling [10–12]. This remarkable feature of
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iPSCs facilitates the study of brain cell types that are diffi-
cult to obtain from living individuals, including human as-
trocytes. To directly examine AxD patient astrocytes, we
established iPSCs from three AxD patients, with different
GFAP mutations, respectively, and three healthy individ-
uals without GFAP mutation. In a recent review of more
than 215 cases of AxD with GFAP mutation, AxD was di-
vided into 2 groups: type I was characterized by early on-
set, seizures, megalencephaly, and typical leukodystrophy
as MRI features, and type II with a later age at onset
characterized by brainstem features and atypical MRI find-
ings [13]. Two patients in this study showed type I clinical
phenotype and one patient showed type II clinical pheno-
type. In this study, AxD iPSC-derived astrocytes showed
GFAP-positive aggregates, like Rosenthal fibers, and also
exhibited altered cytokine release. The strategy of this
study was to provide an effective and versatile way of




Skin or blood samples were obtained from healthy
controls or patients with Alexander disease. The study
was approved by the Institutional Review Board and
Ethics Committees of the University of Kyoto and
Kumamoto University and written informed consent was
obtained from all participants in this study.
Generation of human iPSCs
In this application study, we used dermal fibroblasts
or blood cells as patient somatic cells to prepare iPSCs
[8, 12, 14]. For the iPSC clones of HC1, HC2, HC3,
Alex1, and Alex3, episomal vectors were used to introduce
a reprogramming factor (SOX2, KLF4, OCT4, L-MYC,
LIN28, siRNA for p53) to the somatic cells, which were
seeded onto SNL feeder cells. The next day, the medium
was changed from a dermal fibroblast medium to a
human ES cell medium (ReproCell, Yokohama, Japan)
comprising 4 ng/mL of bFGF (Wako Chemicals, Osaka,
Japan); the medium was replaced every other day, and
after 30 days, about 20 iPSC colonies were picked up.
Later, the presence or absence of residual plasmid was
confirmed by PCR, and clones without residual plasmid
were selected. Selected clones were run through karyotype
analysis, and normal karyotype clones were analyzed. For
the iPSC clones of Alex2, human iPSCs were generated by
using Sendai virus vector as described previously [14].
In vitro differentiation into three germ layers
CTK was used to harvest the iPSCs, and an embryoid
body (EB) was formed [12]. Cell masses were cultured in
DMEM/F12 (Thermo Fisher Scientific, Waltham, MA)
comprising 20 % knockout serum replacement (KSR,
Thermo Fisher Scientific), 2 mM L-glutamine (Thermo
Fisher Scientific), 0.1 M nonessential amino acids (NEAA,
Thermo Fisher Scientific), 0.1 M 2-mercaptoethanol
(Thermo Fisher Scientific), and 0.5 % penicillin/strepto-
mycin. The medium was replaced every other day, and the
EB after 8 days was cultured for another 8 days in DMEM
comprising 10 % FBS on a gelatin-coated coverslip.
Differentiation and enrichment of astrocytes
Human iPSCs were dissociated to single cells and quickly
reaggregated in U-bottom 96-well plates for suspension cul-
ture (Greiner Bio-One, Frickenhausen, Germany), pre-
coated with 2 % Pluronic F-127 (Sigma-Aldrich, St. Louis,
MO) in 100 % ethanol. Cell aggregates, called embryoid
bodies (EBs), were cultured in ‘DFK5% medium’ (DFK5%;
DMEM/F12 (Thermo Fisher Scientific) supplemented with
5 % v/v KSR, 1x NEAA, 1x Glutamax (Thermo Fisher
Scientific), 0.1 M 2-mercaptoethanol (Thermo Fisher
Scientific)) with 2 μM dorsomorphin (Sigma-Aldrich) and
10 μM SB431542 (Cayman Chemical, Ann Arbor, MI) in a
neural inductive stage (day 0 to 8). After neural induction,
EBs were transferred onto Matrigel (Corning, Tewksbury,
MA)-coated 6-well culture plates and cultured in DFK5%
supplemented with 1x N2 supplement (Thermo Fisher
Scientific) and 2 μM dorsomorphin in the patterning stage
(day 8 to 24). A large number of neural stem cells
(NESTIN-positive) were observed to migrate from the EB
core. After the patterning stage, migrated neural stem cells
were separated from the plate bottom using Accutase
(Innovative Cell Technologies, Inc., San Diego, CA) and
cultured in Neurobasal medium FULL, Neurobasal
Medium (Thermo Fisher Scientific) supplemented with 1x
N2 supplement, 1x Glutamax, 10 ng/ml BDNF (Peprotech,
Rocky Hill, NJ), 10 ng/ml GDNF (Peprotech) and 10 ng/ml
NT-3 (Peprotech) on Matrigel-coated 6-well culture plates
or cover-slips (day 24 to 60). At day 60, iPS-derived neural
cells were plated at 400,000-2,000,000 cells per 90-mm dish
without any coating in DMEM/F12 Glutamax (Thermo
Fisher Scientific) supplemented with 1x N2 supplement,
10 ng/ml EGF (Peprotech), 12 ng/ml basic FGF (Peprotech)
and 2 μg/ml heparin (Nacalai Tesque, Kyoto, Japan). After
passage, neurons could not attach to a non-coated polystyr-
ene dish surface or they died by anoikis. On the other hand,
astrocytes and a limited number of oligodendrocyte precu-
sors could attach and proliferate. By repeated passage in the
same manner at days 90, 120, 150 and 180, astrocytes
increased their own abundance ratio and showed positive
GFAP immunostaining.
Immunofluorescent study
The iPSCs or differentiated astrocytes were immobilized
at room temperature for 30 min in 4 % paraformal-
dehyde (pH 7.4), and washed with PBS. The cells were
then permeabilized for 10 min with PBS comprising
0.2 % Triton X-100. A non-specific reaction was also
run for 60 min at room temperature in PBS comprising
10 % donkey serum; primary antibodies were reacted
overnight, and fluorescently labeled secondary antibodies
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were reacted and observed. DAPI (Thermo Fisher Scientific)
was used for nuclear staining. The following primary anti-
bodies were used: NANOG (R&D Systems, Minneapolis,
MN, 1:50), TRA1-60 (Millipore, Darmstadt, Germany,
1:1,000), SOX-17 (R&D Systems, 1:50), αSMA (Dako,
Glostrup, Denmark, 1:3,000), Tuj1 (Covance, 1:3,000),
S100β (Abcam, Cambridge, UK, 1:400), GFAP (DAKO,
1:2,000 or Santa Cruz Biotechnology, Dallas, TX, 1:400),
alpha-B crystallin (Millipore, 1:400), and N-cadherin (Santa
Cruz Biotechnology, 1:50). Rhodamine phalloidin (Thermo
Fisher Scientific, 1:1,000) were used for F-actin staining.
Immunostained cells were analyzed using In Cell Analyzer
6000 (GE Healthcare, Chicago, IL) or the super-resolution
structured illumination microscopy with 100 x objective
lens (N-SIM system, Nikon Instruments, Tokyo, Japan).
Transmission electron microscopy
Briefly, iPSC-derived astrocytes were cultured on plastic
coverslip (CellDesk, Sumitomo Bakelite Co., Ltd., Tokyo,
Japan) and fixed in 4 % paraformaldehyde/2 % glutaral-
dehyde/0.1 M phosphate buffer at 4 °C, washed in iso-
tonic phosphate-buffered sucrose, and then post-fixed in
1 % osmic acid. Specimens were dehydrated with ethanol
and propylene oxide and subsequently embedded in
epoxy resin. Ultrathin sections were cut with an ultrami-
crotome, mounted on grids, stained with uranyl acetate
and lead citrate, and examined by using a Hitachi H-
7650 electron microscope (Hitachi, Tokyo, Japan).
Microarray and pathway analysis for differentiated
astrocytes
Total RNA from differentiated neural cells was extracted
by RNeasy micro kit (QIAGEN, Hilden, Germany) and
altered into ragmented/biotinylated cDNA by GeneChip®
WT PLUS Reagent Kit (Affymetrix, Santa Clara, CA).
Fragmented cDNA samples were hybridized with Gene-
Chip Human Gene 2.0 ST Array (Affymetrix). Each sam-
ple was hybridized once with the one-color protocol.
Arrays were scanned with a GeneChip® Scanner 3000
7Gt (Affymetrix). Data were analyzed by GeneSpring
GX7.3.1 software (Agilent Technologies, Santa Clara,
CA) to create the list of gene sets. The normalized data
have been deposited at Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) with accession
number GSE83374. For pathway analysis, we adopted
gene sets for Ingenuity Pathway Analysis (IPA software,
QIAGEN), and seek altered canonical pathways. To
understand the upstream of pathway changes, the activa-
tion status of the functions/pathways was predicted
using the IPA Upstream Regulator Analysis Tool, by cal-
culating a regulation Z-score and an overlap p-value,
which were based on the number of known target genes
of interest pathways/functions, expression changes of
these target genes and their agreement with literature
findings. It was considered significantly activated (or
inhibited) with an overlap p-value ≤ 0.05 and an IPA
activation Z-score ≥ 1.2 (or ≤ −1.2). The detailed descrip-
tions of IPA analysis are available under “Upstream
Regulator Analysis”, “Biological Functions Analysis”, and
“Ingenuity Canonical Pathways Analysis” on the IPA
website (http://www.ingenuity.com).
Immunoblots
Cells were lysed in RIPA buffer (50 mM Tris-HCl
buffer, pH 8.0, 150 mM NaCl, 1 % NP-40, 0.5 %
deoxycholate, 0.1 % SDS, protease inhibitor cocktail
(Roche Diagnostics, Basel, Switzerland), phosphatase
inhibitor cocktail (Roche Diagnostics)). Each 10 μg
sample of protein was subjected to SDS-PAGE (5-20 %
gradient SDS-polyacrylamide gels, BIOCRAFT, Tokyo,
Japan), and separated proteins were transferred to polyvi-
nylidene fluoride membrane (HybondTM-P, GE Health-
care). The membranes were incubated with primary
antibodies, followed by appropriate secondary antibodies,
and then visualized using ECL prime (GE Healthcare). For
dot-blot analysis, cell lysate samples (each 2 or 4 μg/spot)
were loaded on a nitrocellulose membrane. The mem-
branes were incubated with primary antibodies, followed
by appropriate secondary antibodies, and then visualized
using ECL prime (GE Healthcare). The images were ac-
quired on LAS 4000 (GE Healthcare). The intensity of the
protein band was analyzed using Fiji (http://fiji.sc/). The
following primary antibodies were used: N-cadherin
(1:1,000, Santa Cruz Biotechnology), GAPDH (1:3,000,
Abcam), 4E-BP1 (1:1,000, Cell Signaling Technology
(CST), Danvers, MA), Phospho-4E-BP1 (Ser65) (1:1,000,
CST), eIF4B (1:1,000, CST), Phospho-eIF4B (Ser406)
(1:1,000, CST), eIF4E (1:1,000, Abcam), and Phospho-
eIF4E (Ser209) (1:1,000, Abcam).
Electrochemiluminescence assays for cytokines
Differentiated astroglial cells were replated at 4 x104
cells per well in 96-well plates coated with 0.1 % gelatin.
Three days after replating, all culture medium was
replaced with 100 μL of fresh astrocyte medium. To
assess extracellular cytokine release, conditioned media
were harvested for further analysis. As positive control
of massive cytokines release, 1 μg/mL LPS was added to
NC1 astrocytes. Cytokines in culture media were
measured by human Cytokine Demonstration 10-Plex
tissue Culture Kits (Meso Scale Discovery, Rockville,
MD). This assay uses each antibody to capture each
cytokine and SULFO-TAG-labeled different specific anti-
bodies for detection by electrochemiluminescence with
Sector® Imager 2400 (Meso Scale Discovery). Ten kinds
of cytokines, including IL-1β, IL-2, IL4, IL-5, IL-6, IL-8,
IL-10, IL-12p70, GM-CSF and TNFα, were assayed. The
concentrations of IL-1β, IL4, IL-5, IL-6, GM-CSF and
TNFα were quantified by using standard recombinant
proteins, but the signals of IL-2, IL-8, IL-10 and IL-
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12p70 were not able to be detected in the dynamic range
of the standard curve (0.05-10,000 pg/ml).
Statistics
Comparisons of the mean among three groups or more
were performed by one-way or two-way analysis of
variance (ANOVA) followed by post-hoc test using Tukey–
Kramer method (JMP software version 9.0, SAS Institute
Inc., Cary, NC). P values < 0.05 were considered significant.
Results
Generation and characterization of AxD-specific iPSCs
In the present study, we generated iPSCs from three
AxD patients with heterozygous GFAP mutation (Alex1,
Alex2 and Alex3) and three healthy controls (HC1, HC2,
and HC3) (Table 1). The disease onset of Alex1 and
Alex2 was infantile and that of Alex3 was adult (Table 1).
Primary cultures of somatic cells from all six individuals
were independently reprogrammed to iPSCs, as judged
by colony morphology, similar to human embryonic
stem cells (ESCs), growth dynamics, and sustained long-
term passaging (>20 passages) (Fig. 1a). The established
iPSCs expressed NANOG and TRA1-60, markers of
pluripotency (Fig. 1a). The pluripotency of the iPSCs
was also evaluated in vitro through the formation of
EBs. All iPSC lines spontaneously differentiated into cell
types of the three embryonic germ layers as indicated by
expression of the specific markers, including TUJ1
(ectoderm marker), αSMA (mesoderm marker), and
SOX17 (endoderm marker) (Fig. 1b).
Differentiation of iPSCs into astrocytes
The astrocytic differentiation protocol for human iPSCs
was modified from our previous method [12] (Fig. 2a).
In the neural patterning stage, differentiated cells
expressed NESTIN (marker of neural stem cells) or
GFAP (marker of radial glia in cortical development)
(Fig. 2b). After 2 months, differentiated cells abundantly
expressed TUJ1 (neuronal marker) (Fig. 2b). By repea-
ting low-density passage, differentiated neurons, without
proliferation, failed to attach to the dish and were selec-
tively removed. After five passages and more than 6
months of cultivation, iPSC-derived astrocytes were
enriched (Fig. 2b). Differentiated astrocytes abundantly
expressed S100β (Fig. 2c) and GFAP (Fig. 3a and b),
which are commonly used as astrocytes markers. We did
not observe any obvious difference in astrocytic differen-
tiation efficacy among all individuals (Fig. 2d).
GFAP aggregates in iPSCs-derived astrocytes from AxD
To evaluate the in vitro recapitulation of Rosenthal
fibers, we visualized GFAP of iPSC-derived astrocytes by
immunofluorescent staining. Nearly all iPSC-derived
astrocytes showed positive staining of GFAP (Fig. 3a and
b). GFAP of healthy control astrocytes formed fine
filaments distributed throughout the cytoplasm in a
cytoskeletal array (Fig. 3a, panels of HC1, 2, and 3). In
contrast, a proportion of GFAP in AxD astrocytes
formed fibrous aggregates, similar to Rosenthal fibers of
AxD brain, and also small dot-like patterns (Fig. 3a,
panels of Alex 1, 2, and 3). These fibrous aggregates
were formed in 5-10 % of AxD, and were rarely observed
in healthy controls. Small dot-like aggregates were
formed in 15-20 % of AxD and in a few of the healthy
controls (Fig. 3c). To characterize small dot-like inclu-
sions in detail, we visualized GFAP-positive dots using
super-resolution structured illumination microscopy
(N-SIM system). GFAP-positive dots, with a diameter
of 50-200 nm, showed a cloud-like amorphous struc-
ture, adjacent to normal GFAP filament, and were co-
immunostained with alpha-B crystallin particles (Fig. 4a).
In addition to super-resolution microscopy, we observed
cytosolic aggregates in AxD astrocytes by using electron
microscopy. In AxD astrocytes, electron-attenuated,
granular, or amorphous-appearing structures, surrounded
by filamentous structure, were observed and determined
as Rosenthal fiber-like structures (Fig. 4b). Overexpression
of GFAP might contribute to astrocyte dysfunction in
AxD as was shown in initial studies of overexpressing wild
type GFAP in transgenic mice, which resulted in the for-
mation of Rosenthal fibers indistinguishable from those
found in Alexander disease patients. To investigate the
GFAP dose effects on aggregates formation, we quantified
the GFAP expression and found increased GFAP in AxD
astrocytes (Additional file 1: Figure S1).
Pathway analysis of alteration in global gene expression
patterns
To uncover molecules involved in the AxD astrocyte
pathogenesis, we analyzed global gene expression pro-
files of iPSC-derived astrocytes (Fig. 5a and b). Among
40,716 probe sets, we created a gene set with altered
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Kondo et al. Acta Neuropathologica Communications  (2016) 4:69 Page 4 of 12
expression in AxD astrocytes versus control astrocytes
(fold-change ≥ 2 fold). By adapting this gene set to the
pathway analysis software, we investigated the back-
ground pathway of the AxD pathomechanism. Pathway
analysis revealed altered function of cellular adherence
(Additional file 2: Figure S2) and transcription change
via mTORC1/mTORC2 (Additional file 3: Figure S3).
From the results of cellular adherence pathway ana-
lysis, the expression of cell adhesion molecules (CAM),
including the cadherin family, was altered in AxD astro-
cytes. In iPSC-derived astrocytes of AxD, gene expres-
sion and protein level of N-cadherin were increased, and
those of E-cadherin were decreased (Additional file 2:
Figure S2 and Fig. 6b). Cadherin is known to play an
a
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Fig. 1 Generation of iPSCs from Alexander disease patients and healthy controls. a Morphology and expression of human embryonic stem cell
markers. iPSCs from both controls and patients with Alexander disease showed ESC-like morphology (phase image) and expressed pluripotent
stem cell markers, NANOG and TRA1-60. Scale bars = 200 μm. b In vitro differentiation of established iPSCs to representative three-germ layer:
TUJ1 (ectoderm), αSMA (mesoderm), and SOX17 (endoderm). Scale bars = 50 μm




Fig. 2 iPSCs from AxD patients and healthy controls could differentiate into astrocytes with high purity. a Schematic procedures for astroglial
differentiation. b Differentiated iPSCs at day 24 expressed neural stem cell markers NESTIN and GFAP. Neural cells at day 60 expressed neuronal or
astrocytic marker TUJ1 or GFAP. Most enriched astrocytes expressed GFAP. Scale bars = 20 μm. c Estimation of astroglial differentiation from control
and AxD iPSCs. After 180 days of differentiation, astrocytes were immunostained with an antibody against S100β (red color). Scale bars = 20 μm.
d Calculated purity of astrocytic differentiation Data represent mean ± SD (biological replicates, n = 3 from randomly picked fields per clone).
Two-way analysis of variance (ANOVA) did not show significant variation. F (5, 12) =0.2432; p = 0.935
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important role in the interactions between cells or their
surrounding matrix, and also to affect the cell mor-
phology [15]. The majority of iPSC-derived astrocytes
showed polygonal shape, and less than 20 % showed stel-
late or star-like shape. However, we could not find any
distinct difference in cell shape between control and
AxD astrocytes. To investigate the detailed structural
changes in AxD astrocytes, we performed an immun-
fluorescence study of N-cadherin and F-actin. The signal
intensity of N-cadherin was increased in AxD astrocytes,
but the distribution of N-cadherin or F-actin was similar
between control and AxD (Fig. 6c).
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HC1 HC2 HC3 Alex1 Alex2 Alex3
fibrous aggregates
small dot-like aggregates
Fig. 3 Astrocytes of Alexander disease showed GFAP-positive aggregates. a Most iPSC-derived astrocytes showed GFAP-positive staining (green color).
In healthy control, GFAP showed filamentous structure. In Alexander disease, GFAP mainly showed filamentous structure, but also fibrous/amorphous
(arrows) or dot-like (arrowheads) aggregates. Scale bars = 5 μm. b Calculated purity of astrocytic differentiation data represent mean ± SD (biological
replicates, n = 3 from randomly picked fields per clone). c Calculated positivity of GFAP aggregates. Data represent mean ± SD (biological replicates,
n = 3 from randomly picked fields per clone)
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Additionally, the altered pattern of global gene expres-
sion in AxD astrocytes suggested activation of the mTOR
pathway. Active mTOR promotes protein synthesis by
phosphorylating 4E-BPs on several sites that relieve their
binding to eIF4E, eIF4G or eIF4B. eIF4E mediates binding
of eIF4 large protein complex to the 5’ cap structure of
mRNAs. On the other hand, 4E-BPs in their hypopho-
sphorylated state bind to eIF4E competitively, inhibiting
the association of eIF4E and eIF4G and leading to a block
in translation [16]. Thus, we evaluated mTOR activation
by western blotting with antibodies, specific to phos-
phorylated 4E-BP, eIF4E, eIF4G, and eIF4B (Fig. 6d). As
well as the prediction of pathway analysis, the phos-
phorylation statuses of 4E-BP, eIF4E, eIF4G, and eiF4B
were upregulated in AxD astrocytes (Fig. 6d), indicating
activated mTOR pathway.
To understand the upstream of these two pathway
changes, the activation status of the functions/pathways
was predicted. We can predict that altered gene expression



































Fig. 4 High resolution imaging of aggregates in AxD astrocytes with 3D-SIM or electron microscopy. a Super resolution imaging of GFAP aggregates
with dot-like pattern showed accumulated particles of both GFAP and alpha-B crystalline (CRYAB). Scale bar = 200 nm. b Electron microscopy of AxD
astrocytes. Electron-dense amorphous-appearing structures (open arrow head) or granular (closed arrow head) structures, surrounded by filamentous







































































Fig. 5 Gene expression comparison between healthy control and Alexander’s disease astrocytes. a Scatter plot showing the 2-fold upregulated
and downregulated genes (red and blue dots, respectively) in the astrocytes of Alexander disease. b List of increased and decreased top-20 genes
(red and blue columns, respectively)
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Dysfunction in cell-adherence
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Fig. 6 (See legend on next page.)
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cytokines (Fig. 5c). To test the status of cytokines from
iPSC-derived astrocytes, cytokines secreted in culture
medium were quantified (Fig. 5d). The secretion of GM-
CSF, IL6, IL5 and TNFα was significantly increased in AxD
astrocytes (Fig. 5d). In contrast, the secretion of IL1β and
IL4 was not altered. Additionally, immunostaining study
showed intracellular dots of each cytokine in iPSC-derived
astrocytes (Additional file 4: Figure S4). These results indi-
cated that AxD astrocytes secrete more inflammatory cyto-
kines and affect the neural circumstances of AxD patient
brain.
Discussion
We generated iPSCs from AxD patients and differen-
tiated them into astrocytes exhibiting GFAP-positive
aggregates in cytosol. A part of the cytosolic aggregates
was fibrous and had high immunoreactivity to GFAP
antibody, resembling Rosenthal fibers of AxD brain. On
the other hand, the filamentous structure of GFAP,
which is the major intermediate filament of astrocytes,
was almost absent in astrocytes with fibrous aggregates.
In spite of this, however, we could not find any distinct
morphological alteration in the shape of astrocytes with
fibrous aggregates. We speculate that other species of
intermediate filament proteins, including vimentin, may
have compensated for the diminished GFAP-filament to
maintain the cellular shape [17]. In addition to the
fibrous aggregates, AxD astrocytes displayed small,
round shape of GFAP-positive aggregates, described as a
“small dot-like pattern” in the results. These small dots
were similar to those of previous reports using cancer
cell line models with overexpression of GFAP (overex-
pression models: OE models) [5, 18, 19]. These small
dots in OE models were observed as irregular dots with
or without sand-like diffuse staining patterns. The OE
models with mutant GFAP-aggregates did not show any
normal filamentous pattern of GFAP. However, anti-
GFAP staining of iPSC-derived astrocytes of AxD
showed both normal filamentous structure and small-
dot aggregates in the same cells. Furthermore, the
frequency of the appearance of small-dot aggregates
was greater than that of fibrous aggregates. We
speculate that small-dot aggregates, co-existing with
wild filamentous GFAP, are a premature form of
fibrous aggregates and transformed into fibrous aggre-
gates after a period of time and/or accumulation of
cellular stress. We also could observe electron-dense
amorphous-appearing structures or granular structures,
surrounded by filamentous cytoskeleton. These structures
are similar to Rosenthal fiber in AxD patients brain, but
electron-density of structures in iPSC-derived astrocytes
were not as high as that of AxD brain. Relatively low
electron-density might reflect the early stage of Rosenthal
fiber, which can be an advantage in drug development to
modify early pathomechanisms of AxD.
Secondly, we investigated how GFAP aggregates elicit
the neurodegenerative process. By comparing global-
gene expression between control and AxD astrocytes, we
focused on cell-adhesion pathway and mTOR pathway.
GFAP is an important cytoskeleton protein, but cell
shape and cell proliferation are similar between control
and AxD astrocytes. In our study, the iPSC-derived as-
trocytes were cultivated in the absence of neurons or
other extracellular matrix and might require years of
observation after transplantation into in vivo brain, to
recapitulate morphological phenotypes, such as the
increased ratio of reactive astrocytes. However, N-
cadherin protein was increased in AxD astrocytes. Among
the cadherin family, N-cadherin has been classified as
“nerve-derived”, and is known as a key CAM in the brain.
N-cadherin has also been reported to be upregulated via
cellular-stress signaling after brain injury by using the
N-cadherin knockout model [20]. We speculated that
GFAP aggregates in AxD astrocytes can evoke cellular
stress and upregulated N-cadherin as a stress re-
sponse. In the case of in vivo, altered cell-adhesion
via N-cadherin also might affect the cell-to-cell inter-
action among neurons, oligodendrocytes, microglia
and astrocytes, and consequently could lead to clinical
phenotypes of AxD.
Furthermore, we also focused on activation of the
mTOR pathway. Activation of the mTOR cascade is
known as a characteristic feature of the initial stress
response, and is related to reactive astrocytes in brain
pathologies [21]. According to a previous study by using
GFAP Tg; Gfap+/R236H model mice, the activation
through the mTOR pathway appears to be an early
change, while the later, more severe pathology is
(See figure on previous page.)
Fig. 6 Pathway analysis revealed altered status of cell-adhesion, mTOR, and cytokine release in Alexander disease astrocytes. a Schema of pathway
analysis and upstream prediction analysis. b Whole-cell lysates of iPSC-derived astrocytes were prepared and equivalent amounts of total protein were
loaded per lane on a polyacrylamide gel for Western blot (WB) analysis using N-cadherin or GAPDH antibodies shown on the left. c Astrocytes were
immunostained with an antibody against N-cadherin (green color) and F-actin (red color) was also visualized by using Rhodamine phalloidin. Scale
bar = 10 μm. d Whole-cell lysates were prepared and equivalent amounts of total protein were loaded per lane on a polyacrylamide gel for WB
analysis using the panel of antibodies shown on the left. The values shown below each blot represent the ratio of phosphorylated/total band densities,
calculated and normalized to the ratio in “HC1” astrocytes. e Quantification of cytokine release from iPSC-derived astrocytes. Gray/pink-colored columns
indicate astrocytes of healthy controls/Alexander disease. Black-colored column indicates healthy astrocytes with addition of LPS as positive control of
cytokine release. LPS: lipopolysaccharide. (*, p < 0.05, N.S.: not significant) Data represent mean ± SD (biological replicates, n = 3)
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accompanied by mTOR inactivation [22]. Considering
these pieces of evidence, our iPSC-derived astrocytes re-
flect the early phase of the AxD pathomechanism, and
should be applicable to the development of drugs for an
initial insult of GFAP aggregates.
Previous neuropathological investigations have described
that lymphocytic infiltration or microglial activation was
not massive in AxD brain [2, 23]. Olanbarria et al. investi-
gated detailed alteration of the cytokine network in AxD
model mice with both OE of human wild-type GFAP and
heterozygous knock-in of mice Gfap R236H, and detected
inflammatory response [24]. Consistent with this report, in
our study, AxD astrocytes from patient iPSCs exhibited in-
creased amounts of secreted GM-CSF, IL5, IL6, and TNFα.
GM-CSF, IL6, and TNFα are well known as proinflamma-
tory cytokines and are upregulated in various kinds of
white matter diseases, including multiple sclerosis (MS)
and neuromyelitis optica (NMO) [25–28]. IL-5 is a Th2
cell-type cytokine that is secreted by astrocytes and micro-
glia [29], turning on the switch of inflammatory response
by activating microglia to upregulate inflammatory re-
sponse in the brain, cooperating with GM-CSF [30, 31].
IL-5 is also upregulated not only in inflammatory condi-
tions with parasitic infections but also in neurodegener-
ative disorders, including Parkinson’s disease [32]. In
addition, clinically, AxD, especially type 2, shows step-
wise or stroke-like progression, which is similar to the
typical progression of other white matter diseases
involving oligodendrocytes, MS and NMO. These find-
ings suggest that the neuroinflammatory process pro-
moted by proinflammatory astrocytes may be involved
in the pathogenesis of AxD, and that immunomodula-
tion approaches [33] targeting astrocytopathy would be
a candidate therapy for AxD. Recent studies showed
that astrocytes themselves can secrete cytokines and
have responsibility for extrinsic factors, including LPS
[34–36]. The cell population of iPSC-derived astrocytes
did not show microglial markers. So, astrocyte-derived
cytokines and chemokines might play both neuropro-
tective and neurotoxic roles in AxD, and could be a
phenotypic target of future drug development by the
use of an iPSC-derived astrocyte platform.
Conclusions
iPSCs from AxD patients were used to clarify disease phe-
notypes of astrocytes, which are the target cells of AxD.
iPSC-derived astrocytes from AxD patients showed
GFAP-aggregates resembling Rothental fibers and altered
release of cytokines such as in white matter disease.
Patient-specific iPSCs of AxD would provide a feasible
platform for the study of inherited astrocytopathies, and
further studies focusing on pathological crosstalk between
astrocytes and other types of cells in the brain might lead
to novel therapies for AxD.
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